Carfilzomib
- PR-171
Axon 4218
CAS:
868540-17-4
- Optical Purity: Optically pure
- Soluble in DSMO
- MF: C40H57N5O7
- MW: 719.91
Description
An epoxomicin derivate with potential antineoplastic activity. It irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.
More Information
| Parent CAS No. | 868540-17-4 |
|---|---|
| Chemical Name | (S)-4-methyl-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | N1(CCOCC1)CC(=O)N[C@@H](CCC1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(CO1)C |&1:10,22,30,41,48,r| |
| MFCD | N.A. |
| InChi | N.A. |
| InChiKey | N.A. |
| CID | N.A. |
| Short Description | Proteasome inhibitor |
References
- G Cavaletti et al. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma. 2010 Jul;51(7):1178-87.
- Kuhn DJ et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 2256 | Biotinyl-phenylboronic acid |
From $319.00 |
| 2257 | Dansyl-PEG-phenylboronic acid |
From $396.00 |
| 3849 | Oprozomib |
From Inquiry |
Other Categories
Get a Quote for
Loading...